Although additional research is needed to confirm our findings, our study demonstrates that ST2 can be considered a PAD-specific biomarker, as it was the only protein that was significantly elevated in patients with PAD and predicted the development of adverse limb events over a 2-year follow-up period. Here, IL1RL1 is linked to peripheral arterial disease.